Panacea Biotec Limited
Panacea Biotec Limited (PANACEABIO) financial statements and selected valuation metrics from NSE/BSE exchange filings through 30 June 2026.
Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals
panaceabiotec.com(opens the company website in a new tab)Key metrics
Price as of 2026-09-03
Stock price
₹389.05
Market cap
2,385 Cr
Stock P/E
265.6
P/B
2.88
Sign in for full ratios and TTM. Learn about these metrics →
Share price
NSE closing price from historical market data.
Loading price history…
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024BSE balance sheet (this exchange's own filing had none for this period) | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 143 Cr | 151 Cr | 136 Cr | 116 Cr | 147 Cr | 163 Cr | 133 Cr | 167 Cr | 141 Cr | 165 Cr | 167 Cr | 200 Cr |
| Operating expenses (approx.) | 147 Cr | 151 Cr | 143 Cr | 130 Cr | 140 Cr | 156 Cr | 159 Cr | 168 Cr | 159 Cr | 153 Cr | 164 Cr | 194 Cr |
| EBITDA | -4 Cr | -0.15 Cr | -6 Cr | -14 Cr | 7 Cr | 8 Cr | -27 Cr | -1 Cr | -18 Cr | 12 Cr | 3 Cr | 6 Cr |
| OPM % | -2.5% | -0.1% | -4.4% | -12.1% | 4.8% | 4.9% | -20.3% | -0.7% | -12.6% | 7.1% | 1.5% | 2.8% |
| Other income | 3 Cr | 6 Cr | 11 Cr | 4 Cr | 5 Cr | 4 Cr | 9 Cr | 6 Cr | 6 Cr | 2 Cr | 3 Cr | 4 Cr |
| Interest | 0.91 Cr | 0.85 Cr | 0.82 Cr | 0.87 Cr | 0.98 Cr | 0.99 Cr | 1 Cr | 0.86 Cr | 2 Cr | 2 Cr | 1 Cr | 1 Cr |
| Depreciation | 9 Cr | 9 Cr | 9 Cr | 9 Cr | 9 Cr | 9 Cr | 8 Cr | 8 Cr | 8 Cr | 8 Cr | 8 Cr | 8 Cr |
| Profit before tax | -8 Cr | -2 Cr | -2 Cr | -17 Cr | 5 Cr | 4 Cr | -0.04 Cr | 7 Cr | -19 Cr | 6 Cr | -1 Cr | 4 Cr |
| Tax % | -6.6% | -33.3% | 6.1% | 6.9% | 1.1% | -1.4% | -4875.0% | 39.6% | 26.9% | 40.1% | 20.0% | 38.4% |
| Net profit | -8 Cr | -2 Cr | -2 Cr | -16 Cr | 5 Cr | 4 Cr | -2 Cr | 4 Cr | -14 Cr | 4 Cr | -1 Cr | 2 Cr |
| EPS (₹) | ₹-1.35 | ₹-0.37 | ₹-0.23 | ₹-2.59 | ₹0.77 | ₹0.74 | ₹-0.31 | ₹0.66 | ₹-2.27 | ₹0.65 | ₹0.08 | ₹0.38 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2020 | Mar 2021 | Mar 2022BSE balance sheet (this exchange's own filing had none for this period) | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales | 544 Cr | 625 Cr | 661 Cr | 460 Cr | 559 Cr | 559 Cr | 640 Cr | Sign in for TTM |
| Operating expenses (approx.) | 513 Cr | 548 Cr | 675 Cr | 558 Cr | 579 Cr | 585 Cr | 644 Cr | Sign in for TTM |
| EBITDA | 31 Cr | 77 Cr | -14 Cr | -98 Cr | -20 Cr | -26 Cr | -5 Cr | Sign in for TTM |
| OPM % | 5.8% | 12.3% | -2.1% | -21.3% | -3.6% | -4.6% | -0.7% | Sign in for TTM |
| Other income | 30 Cr | 10 Cr | 11 Cr | 52 Cr | 26 Cr | 21 Cr | 17 Cr | Sign in for TTM |
| Interest | 174 Cr | 185 Cr | 181 Cr | 4 Cr | 4 Cr | 4 Cr | 6 Cr | Sign in for TTM |
| Depreciation | 43 Cr | 46 Cr | 44 Cr | 39 Cr | 37 Cr | 35 Cr | 33 Cr | Sign in for TTM |
| Profit before tax | -178 Cr | -145 Cr | 1,449 Cr | 13 Cr | 1 Cr | -8 Cr | -7 Cr | Sign in for TTM |
| Tax % | -9.4% | -1.4% | 25.6% | 363.7% | 201.4% | -9.7% | 2.8% | Sign in for TTM |
| Net profit | -194 Cr | -148 Cr | 1,078 Cr | -34 Cr | -1 Cr | -9 Cr | -7 Cr | Sign in for TTM |
| EPS (₹) | ₹-31.72 | ₹-24.11 | ₹175.98 | ₹-5.51 | ₹-0.19 | ₹-1.37 | ₹-0.88 | Sign in for TTM |
| Dividend payout % | — | — | 0.0% | — | — | — | — | Sign in for TTM |
Sign in for TTM
Trailing twelve months totals and margin rows
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2020 | Mar 2021 | Mar 2022BSE balance sheet (this exchange's own filing had none for this period) | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Equity capital | 6 Cr | 6 Cr | 6 Cr | 6 Cr | 6 Cr | 6 Cr | 6 Cr |
| Reserves | 171 Cr | -276 Cr | 843 Cr | 837 Cr | 836 Cr | 829 Cr | 829 Cr |
| Borrowings | — | — | 34 Cr | 20 Cr | 21 Cr | 22 Cr | 24 Cr |
| Other liabilities | 890 Cr | 1,412 Cr | 903 Cr | 411 Cr | 381 Cr | 437 Cr | 410 Cr |
| Total liabilities | 1,067 Cr | 1,142 Cr | 1,783 Cr | 1,271 Cr | 1,241 Cr | 1,290 Cr | 1,262 Cr |
| Fixed assets (net) | — | — | 588 Cr | 588 Cr | 560 Cr | 543 Cr | 553 Cr |
| CWIP | — | — | 5 Cr | 28 Cr | 75 Cr | 94 Cr | 100 Cr |
| Investments | — | — | 5 Cr | 13 Cr | 53 Cr | 19 Cr | 26 Cr |
| Loans & advances | — | — | 1 Cr | 2 Cr | 3 Cr | 3 Cr | 2 Cr |
| Inventories | — | — | 213 Cr | 202 Cr | 178 Cr | 214 Cr | 193 Cr |
| Trade receivables | — | — | 132 Cr | 60 Cr | 57 Cr | 73 Cr | 74 Cr |
| Cash & bank | — | — | 50 Cr | 40 Cr | 47 Cr | 82 Cr | 57 Cr |
| Other assets | 1,067 Cr | 1,142 Cr | 789 Cr | 338 Cr | 267 Cr | 263 Cr | 258 Cr |
| Total assets | 1,067 Cr | 1,142 Cr | 1,783 Cr | 1,271 Cr | 1,241 Cr | 1,290 Cr | 1,262 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2020 | Mar 2021 | Mar 2022BSE balance sheet (this exchange's own filing had none for this period) | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Cash from operating activity | — | — | -108 Cr | -423 Cr | -0.10 Cr | -27 Cr | 17 Cr |
| Cash from investing | — | — | 1,283 Cr | 430 Cr | 10 Cr | 65 Cr | -40 Cr |
| Cash from financing | — | — | -1,176 Cr | -18 Cr | -3 Cr | -3 Cr | -1 Cr |
| Net cash flow | — | — | -2 Cr | -11 Cr | 7 Cr | 35 Cr | -25 Cr |
| Free cash flow (OCF − Capex) | — | — | -121 Cr | -464 Cr | -78 Cr | -78 Cr | -37 Cr |
Ratios
Ratios as reported or derived per annual period.
| Metric | Mar 2020 | Mar 2021 | Mar 2022BSE balance sheet (this exchange's own filing had none for this period) | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| ROCE % | -2.1% | — | 192.0% | 2.0% | 0.6% | -0.5% | -0.2% |
| ROE % | -109.8% | — | 127.0% | 0.0% | -0.1% | -1.0% | -0.6% |
| Debtor days | — | — | 72 | 48 | 37 | 47 | 42 |
| Inventory days | — | — | 275 | 349 | 309 | 363 | 242 |
| Days payable | — | — | 336 | 306 | 267 | 384 | 238 |
| Cash conversion cycle | — | — | 12 | 90 | 80 | 27 | 46 |
| Debt / equity | — | — | 0.04 | 0.02 | 0.03 | 0.03 | 0.03 |
| Current ratio | — | — | 1.25 | 1.71 | 1.57 | 1.49 | 1.47 |
| Net debt / EBITDA | 0.00 | 0.00 | — | — | — | — | — |
Compare with peers
Loading peers…